BDBM493091 2-((1r,4r)-4-(2-(4-Chloro-1H-pyrazol-3-yl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile::US10981911, Example 31

SMILES Clc1c[nH]nc1-c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1

InChI Key InChIKey=JRUFFDAPSGAZIL-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 493091   

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493091(US10981911, Example 31 | 2-((1r,4r)-4-(2-(4-Chloro...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493091(US10981911, Example 31 | 2-((1r,4r)-4-(2-(4-Chloro...)
Affinity DataIC50: 5.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493091(US10981911, Example 31 | 2-((1r,4r)-4-(2-(4-Chloro...)
Affinity DataIC50: 121nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493091(US10981911, Example 31 | 2-((1r,4r)-4-(2-(4-Chloro...)
Affinity DataIC50: 3.70nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In DepthDetails
US Patent